雷莫西尤单抗联合化疗二线治疗晚期胃癌的临床研究

Clinical study of Remoxiumab combined with chemotherapy in second-line treatment of advanced gastric cancer

目的 探讨雷莫西尤单抗联合化疗二线治疗晚期胃癌的价值。方法 选择2022年5月-2023年5月资阳市第一人民医院肿瘤科收治的80例晚期胃癌患者,随机分为两组。对照组(40例)接受紫杉醇化疗,观察组(40例)接受雷莫西尤单抗联合紫杉醇治疗。观察疗效、不良反应、生存时间以及血清肿瘤标志物和生存质量。结果 观察组疾病控制率(DCR)(85.00%vs 65.00%)和客观缓解率(ORR)(45.00%vs 22.50%)高于对照组(P<0.05),中位无进展生存(PFS)时间长于对照组(6.1月vs 4.0月),中位总生存(OS)长于对照组(9.0个月vs 6.1个月)(P<0.05)。观察组治疗后血清癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原199(CA199)水平低于对照组(P<0.05),生活质量核心问卷量表(QLQ-C30)评分高于对照组(P<0.05)。结论 雷莫西尤单抗联合化疗二线治疗晚期胃癌可提高疾病控制率,延长生存期,改善生存质量,安全性可控。

Objective Objective To value of remoxiumab combined with chemotherapy in second-line treatment of advanced gastric cancer.Methods 80 patients with advanced gastric cancer admitted to Cancer Department of Ziyang First People′s Hospital from May 2022 to May 2023 were randomly divided into two groups.The control group(40 cases) received paclitaxel chemotherapy,and the observation group(40 cases) received remoxiumab combined with paclitaxel.Efficacy,adverse reactions,survival time,serum tumor markers and quality of life were observed.Results The disease control rate(DCR)(85.00% vs 65.00%)and objective response rate(ORR)(45.00% vs 22.50%)of the observation group were higher than those of the control group(P<0.05),the median progression-free survival(PFS) time was longer than that of the control group(6.1 months vs 4.0 months),and the median overall survival(OS) was longer than that of the control group(9.0 months vs 6.1 months)(P<0.05).The levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125) and carbohydrate antigen 199(CA199) in serum of observation group after treatment were lower than those of control group(P<0.05),and the score of core quality of Life questionnaire(QLQ-C30) was higher than that of control group(P<0.05).Conclusion Remoxiumab combined with chemotherapy in second-line treatment of advanced gastric cancer can increase disease control rate,prolong survival,improve quality of life,and have controllable safety.